These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 32820119)

  • 21. Whole protein and defined CD8(+) and CD4(+) peptides linked to penetratin targets both MHC class I and II antigen presentation pathways.
    Pouniotis DS; Esparon S; Apostolopoulos V; Pietersz GA
    Immunol Cell Biol; 2011 Nov; 89(8):904-13. PubMed ID: 21383765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapy: natural versus synthetic peptides.
    Protti MP; Bellone M
    Immunol Today; 1998 Feb; 19(2):98. PubMed ID: 9509766
    [No Abstract]   [Full Text] [Related]  

  • 23. CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination.
    Ahrends T; Bąbała N; Xiao Y; Yagita H; van Eenennaam H; Borst J
    Cancer Res; 2016 May; 76(10):2921-31. PubMed ID: 27020860
    [TBL] [Abstract][Full Text] [Related]  

  • 24. T-cell epitope strength in WAP-T mouse mammary carcinomas is an important determinant in PD1/PD-L1 immune checkpoint blockade therapy.
    Bruns M; Wanger J; Schumacher U; Deppert W
    Oncotarget; 2016 Oct; 7(40):64543-64559. PubMed ID: 27579535
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The cationic region from HIV tat enhances the cell-surface expression of epitope/MHC class I complexes.
    Leifert JA; Holler PD; Harkins S; Kranz DM; Whitton JL
    Gene Ther; 2003 Dec; 10(25):2067-73. PubMed ID: 14595379
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization.
    Rekoske BT; Smith HA; Olson BM; Maricque BB; McNeel DG
    Cancer Immunol Res; 2015 Aug; 3(8):946-55. PubMed ID: 26041735
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The assembly of functional beta(2)-microglobulin-free MHC class I molecules that interact with peptides and CD8(+) T lymphocytes.
    Schell TD; Mylin LM; Tevethia SS; Joyce S
    Int Immunol; 2002 Jul; 14(7):775-82. PubMed ID: 12096037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improving immunotherapy by conditionally enhancing MHC class I presentation of tumor antigen-derived Peptide epitopes.
    Storkus WJ; Herrem C; Kawabe M; Cohen PA; Bukowski RM; Finke JH; Wesa AK
    Crit Rev Immunol; 2007; 27(5):485-93. PubMed ID: 18197809
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MHC class I presented antigens from malignancies: A perspective on analytical characterization & immunogenicity.
    Schmidt M; Lill JR
    J Proteomics; 2019 Jan; 191():48-57. PubMed ID: 29698800
    [TBL] [Abstract][Full Text] [Related]  

  • 30. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand.
    Overwijk WW; Tsung A; Irvine KR; Parkhurst MR; Goletz TJ; Tsung K; Carroll MW; Liu C; Moss B; Rosenberg SA; Restifo NP
    J Exp Med; 1998 Jul; 188(2):277-86. PubMed ID: 9670040
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.
    Sivan A; Corrales L; Hubert N; Williams JB; Aquino-Michaels K; Earley ZM; Benyamin FW; Lei YM; Jabri B; Alegre ML; Chang EB; Gajewski TF
    Science; 2015 Nov; 350(6264):1084-9. PubMed ID: 26541606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy.
    Wang Y; Ma R; Liu F; Lee SA; Zhang L
    Front Immunol; 2018; 9():374. PubMed ID: 29556232
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence for cytotoxic T lymphocyte response against human lung cancer: reconstitution of antigenic epitope with peptide eluted from lung adenocarcinoma MHC class I.
    Calhoun RF; Naziruddin B; Enriquez-Rincon F; Duffy BF; Ritter JM; Sundaresan S; Patterson GA; Cooper JD; Mohanakumar T
    Surgery; 2000 Jul; 128(1):76-85. PubMed ID: 10876189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. T-cell-receptor-like antibodies - generation, function and applications.
    Dahan R; Reiter Y
    Expert Rev Mol Med; 2012 Feb; 14():e6. PubMed ID: 22361332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity.
    Tanoue T; Morita S; Plichta DR; Skelly AN; Suda W; Sugiura Y; Narushima S; Vlamakis H; Motoo I; Sugita K; Shiota A; Takeshita K; Yasuma-Mitobe K; Riethmacher D; Kaisho T; Norman JM; Mucida D; Suematsu M; Yaguchi T; Bucci V; Inoue T; Kawakami Y; Olle B; Roberts B; Hattori M; Xavier RJ; Atarashi K; Honda K
    Nature; 2019 Jan; 565(7741):600-605. PubMed ID: 30675064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Manipulation of avidity to improve effectiveness of adoptively transferred CD8(+) T cells for melanoma immunotherapy in human MHC class I-transgenic mice.
    Bullock TN; Mullins DW; Colella TA; Engelhard VH
    J Immunol; 2001 Nov; 167(10):5824-31. PubMed ID: 11698456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct identification of human tumor-associated peptide antigens and a preclinical model to evaluate their use.
    Engelhard VH; Bullock TN; Colella TA; Mullins DW
    Cancer J; 2000 May; 6 Suppl 3():S272-80. PubMed ID: 10874498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.
    Aarntzen EH; De Vries IJ; Lesterhuis WJ; Schuurhuis D; Jacobs JF; Bol K; Schreibelt G; Mus R; De Wilt JH; Haanen JB; Schadendorf D; Croockewit A; Blokx WA; Van Rossum MM; Kwok WW; Adema GJ; Punt CJ; Figdor CG
    Cancer Res; 2013 Jan; 73(1):19-29. PubMed ID: 23087058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human MHC class I transgenic mice deficient for H2 class I expression facilitate identification and characterization of new HLA class I-restricted viral T cell epitopes.
    Cheuk E; D'Souza C; Hu N; Liu Y; Lang H; Chamberlain JW
    J Immunol; 2002 Nov; 169(10):5571-80. PubMed ID: 12421934
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis.
    Seo N; Tokura Y; Nishijima T; Hashizume H; Furukawa F; Takigawa M
    Proc Natl Acad Sci U S A; 2000 Jan; 97(1):371-6. PubMed ID: 10618425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.